Search for: "Novartis Pharmaceuticals Inc"
Results 81 - 100
of 393
Sort by Relevance
|
Sort by Date
18 Mar 2016, 2:04 pm
Novartis Pharmaceuticals Corp., No. [read post]
3 Mar 2016, 5:19 am
Novartis Pharmaceuticals Corp., 247 P.3d 244, 257 (Mont. 2010); Downing v. [read post]
30 Nov 2015, 1:25 pm
Novartis Pharmaceuticals Corp., 944 F. [read post]
6 Nov 2015, 6:58 am
Therefore, it was not obvious to test pregabalin – it might be obvious to test gabapentin, but even here the judge considered that the skilled team would have little expectation of success.InsufficiencyAccording to the caselaw relating to sufficiency developed in MedImmune Ltd v Novartis Pharmaceuticals UK Ltd [2011] EWHC 1699 (Pat) at [458]-[484] and summarised in Sandvik Intellectual Property AB v Kennametal UK Ltd [2011] EWHC 3311 (Pat) at… [read post]
22 Oct 2015, 8:42 am
IMS Health, Inc., 131 S. [read post]
17 Oct 2015, 5:29 am
Novartis Pharms., No. 5:11–CV–680–D, 2013 WL 4854488, at *3 (Sept. 11, 2013). [read post]
8 Oct 2015, 5:00 am
Novartis Pharmaceuticals Corp., 894 F. [read post]
24 Aug 2015, 5:00 am
Abbott Laboratories, Inc., ___ F. [read post]
11 Aug 2015, 9:34 am
Andrews in Novartis Pharmaceuticals Corp., et al. v. [read post]
6 Aug 2015, 2:08 pm
Sales of Biogen Inc's Tecfidera and Tysabri had been affected by reports of the rare brain infection. [read post]
26 Jun 2015, 12:30 am
Actually, Mr Justice Arnold had himself moved away from the idea already - he distinguished his decision in the later case of Idenix Pharmaceutical, Inc v Gilead Sciences, Inc (reported by IPKat here) in which he declined to construe a claim narrowly on the basis of the prosecution history.This did not however have any effect on the outcome - Floyd LJ otherwise endorsed Arnold J's application of the Protocol questions to likewise find that there was no direct… [read post]
26 May 2015, 7:42 am
Claims such as in Mills, which are at loggerheads with FDA criteria for drug development, are precisely those with the most potential for making pharmaceutical manufacturers into “sitting ducks” for litigation, in this instance litigation based on extraneous genetic factors.It may well be that the coming (and to some extent existing) revolution in genetically individualized medical therapy will require changes in how drugs are evaluated, labeled, etc., but this is a… [read post]
25 May 2015, 4:15 am
******************PREVIOUSLY, ON NEVER TOO LATENever too late 46 [week ending on Sunday 17 May] – Whyte & MacKay Ltd v Origin Wine UK Ltd and Dolce Co Invest Inc | "Three aspects of information: Current issues in trade secrets, client confidentiality and privilege" -- a new event | CJEU upon distribution right in Dimensione Direct Sales srl and Michele Labianca v Knoll International SpA| UK Supreme Court on Mere reputation and passing-off |… [read post]
23 May 2015, 10:24 pm
Two recent decisions issued by the Australian Patent Office address the requirements for extending the term of a patent encompassing a pharmaceutical substance ‘when produced by a process that involves the use of recombinant DNA technology’: ImmunoGen, Inc. [2014] APO 88 and Novartis Vaccines and Diagnostics S.r.l. [2015] APO 2.What is interesting about both these cases is that, while recombinant DNA techniques are employed in manufacturing the… [read post]
18 May 2015, 11:01 am
******************PREVIOUSLY, ON NEVER TOO LATENever too late 45 [week ending on Sunday 10 May] – INTA 2015 and the Kat | IP and Competition Law | Sky v Skype | CJEU v Spain | Digital Single Market Strategy | IPCom v HTC | European Qualifying Examination appealed | UPC fees | CJEU and 3-D marks | EPO Oral Proceedings.Never too late 44 [week ending on Sunday 3 May] – Forgotten principles and histories, and the role of complexity in patent law… [read post]
3 May 2015, 10:33 pm
******************PREVIOUSLY, ON NEVER TOO LATENever too late 42 [week ending on Sunday 26 April] – C5's annual Pharmaceutical Patent Term Extensions Forum | UPC: patent attorney and client discuss | CJEU’s 2014 report | PUMA v PUDEL | Leaked Digital Single Market Strategy | Again of the EU Patent Package and alleged dangers| EU TM reform | Is Svensson’s new public ok? [read post]
25 Apr 2015, 11:03 am
The first edition of the Reference Manual on Scientific Evidence [Manual] was published in 1994, a year after the Supreme Court delivered its opinion in Daubert. [read post]
9 Apr 2015, 5:00 am
Novartis Pharmaceuticals Corp., 2011 WL 1533467, at *9-10 (E.D.N.Y. [read post]
19 Mar 2015, 5:00 am
Novartis AG, ___ F. [read post]
16 Feb 2015, 1:44 am
* "Fool's errand": no need to create your own brand if you can use someone else's Jeremy notes Speciality European Pharma Ltd v Doncaster Pharmaceuticals Group Ltd & Madaus GmbH [2015] EWCA Civ 54 [on which see earlier katpost here], a trade mark infringement decision of the Court of Appeal, England and Wales, on parallel importation and over-stickering of pharmaceutical products. [read post]
